# Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination

> **NCT07232706** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Centre Hospitalier Annecy Genevois** · enrollment: 1000 (estimated)

## Conditions studied

- RSV Immunization

## Interventions

- **DRUG:** Nirsevimab
- **DRUG:** Abrysvo

## Key facts

- **NCT ID:** NCT07232706
- **Lead sponsor:** Centre Hospitalier Annecy Genevois
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232706, "Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07232706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*